BACKGROUND & AIMS: Several studies have reported hepatitis C virus (HCV) RNA sequences in the circulation after treatment-induced or spontaneous recovery. We investigated whether the HCV RNA represents persistence of HCV infection or reinfection. METHODS: We studied 117 patients who recovered from HCV infection (98 following therapy and 19 spontaneously). A reverse-transcription polymerase chain reaction assay was used to detect the 5'-untranslated region of HCV. T-cell responses were studied by enzyme-linked immunospot for interferon-γ. RESULTS: Plasma samples from 15% of treatment-recovered patients and no spontaneously recovered patient tested positive for HCV RNA. Lymphocytes from 3 patients who responded to therapy and 1 who recovered spontaneously tested positive. The frequency of HCV RNA detection in plasma correlated inversely with the time after the end of treatment. Post-treatment HCV 5'-untranslated region sequences matched pretreatment sequences in 85% of cases. T-cell responses were significantly greater at time points with detectable trace amounts of HCV RNA than at time points without detectable HCV RNA (P = .035) and were primarily against nonstructural HCV antigens. The immune hierarchy was preserved over 5 years in patients whose post-treatment HCV RNA sequences matched pretreatment sequences, indicating HCV RNA persistence. An altered immune hierarchy with dominant immune responses, shifting from nonstructural to structural antigens, was observed in a single patient whose post-treatment HCV genotype differed from that of the pretreatment genotype, indicating HCV reinfection. CONCLUSIONS: Trace amounts of HCV RNA of pretreatment sequence persisted and reappeared sporadically in the circulation within 8 years after recovery from hepatitis C but not thereafter, indicating that patients are cured of HCV infection. Reappearance of HCV RNA induced HCV-specific T-cell responses.
BACKGROUND & AIMS: Several studies have reported hepatitis C virus (HCV) RNA sequences in the circulation after treatment-induced or spontaneous recovery. We investigated whether the HCV RNA represents persistence of HCV infection or reinfection. METHODS: We studied 117 patients who recovered from HCV infection (98 following therapy and 19 spontaneously). A reverse-transcription polymerase chain reaction assay was used to detect the 5'-untranslated region of HCV. T-cell responses were studied by enzyme-linked immunospot for interferon-γ. RESULTS: Plasma samples from 15% of treatment-recovered patients and no spontaneously recovered patient tested positive for HCV RNA. Lymphocytes from 3 patients who responded to therapy and 1 who recovered spontaneously tested positive. The frequency of HCV RNA detection in plasma correlated inversely with the time after the end of treatment. Post-treatment HCV 5'-untranslated region sequences matched pretreatment sequences in 85% of cases. T-cell responses were significantly greater at time points with detectable trace amounts of HCV RNA than at time points without detectable HCV RNA (P = .035) and were primarily against nonstructural HCV antigens. The immune hierarchy was preserved over 5 years in patients whose post-treatment HCV RNA sequences matched pretreatment sequences, indicating HCV RNA persistence. An altered immune hierarchy with dominant immune responses, shifting from nonstructural to structural antigens, was observed in a single patient whose post-treatment HCV genotype differed from that of the pretreatment genotype, indicating HCV reinfection. CONCLUSIONS: Trace amounts of HCV RNA of pretreatment sequence persisted and reappeared sporadically in the circulation within 8 years after recovery from hepatitis C but not thereafter, indicating that patients are cured of HCV infection. Reappearance of HCV RNA induced HCV-specific T-cell responses.
Authors: Chihiro Morishima; Timothy R Morgan; James E Everhart; Elizabeth C Wright; Minjun C Apodaca; David R Gretch; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; William M Lee; Anna S F Lok; Jules L Dienstag; Marc G Ghany; Teresa M Curto Journal: Hepatology Date: 2008-11 Impact factor: 17.425
Authors: Bart J Veldt; E Jenny Heathcote; Heiner Wedemeyer; Juerg Reichen; W Peter Hofmann; Stefan Zeuzem; Michael P Manns; Bettina E Hansen; Solko W Schalm; Harry L A Janssen Journal: Ann Intern Med Date: 2007-11-20 Impact factor: 25.391
Authors: Liisa K Selin; Michael A Brehm; Yuri N Naumov; Markus Cornberg; Sung-Kwon Kim; Shalyn C Clute; Raymond M Welsh Journal: Immunol Rev Date: 2006-06 Impact factor: 12.988
Authors: Tram N Q Pham; Dawn King; Sonya A Macparland; Jerry S McGrath; S Bharati Reddy; Ford R Bursey; Tomasz I Michalak Journal: Gastroenterology Date: 2007-12-14 Impact factor: 22.682
Authors: T N Q Pham; P M Mulrooney-Cousins; S E Mercer; S A MacParland; M Inglot; M Zalewska; K Simon; T I Michalak Journal: J Viral Hepat Date: 2007-08 Impact factor: 3.728
Authors: Kei Fujiwara; Robert D Allison; Richard Y Wang; Patricia Bare; Kentaro Matsuura; Cathy Schechterly; Krishna Murthy; Francesco M Marincola; Harvey J Alter Journal: Hepatology Date: 2012-12-06 Impact factor: 17.425
Authors: Koji Hara; Maria M Rivera; Christopher Koh; Mary Demino; Sandra Page; Pothu Raju Nagabhyru; Barbara Rehermann; T Jake Liang; Jay H Hoofnagle; Theo Heller Journal: J Infect Dis Date: 2013-10-14 Impact factor: 5.226
Authors: Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga Journal: World J Gastroenterol Date: 2012-06-21 Impact factor: 5.742
Authors: A Rivero-Juarez; A Caruz; L M Real; L Martinez-Dueñas; F J Marquez; M Frias; E Recio; A Gordon; J A Pineda; A Rivero; A Camacho Journal: Eur J Clin Microbiol Infect Dis Date: 2015-08-09 Impact factor: 3.267